6.
Vachon-Presseau E
. Effects of stress on the corticolimbic system: implications for chronic pain. Prog Neuropsychopharmacol Biol Psychiatry. 2017; 87(Pt B):216-223.
DOI: 10.1016/j.pnpbp.2017.10.014.
View
7.
Gungor D, Kruijshaar M, Plug I, Rizopoulos D, Kanters T, Wens S
. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis. 2015; 39(2):253-60.
PMC: 4754323.
DOI: 10.1007/s10545-015-9889-6.
View
8.
Tucker-Bartley A, Lemme J, Gomez-Morad A, Shah N, Veliu M, Birklein F
. Pain Phenotypes in Rare Musculoskeletal and Neuromuscular Diseases. Neurosci Biobehav Rev. 2021; 124:267-290.
PMC: 9521731.
DOI: 10.1016/j.neubiorev.2021.02.009.
View
9.
Randall E, Smith K, Conroy C, Smith A, Sethna N, Logan D
. Back to Living: Long-term Functional Status of Pediatric Patients Who Completed Intensive Interdisciplinary Pain Treatment. Clin J Pain. 2018; 34(10):890-899.
DOI: 10.1097/AJP.0000000000000616.
View
10.
Korlimarla A, Lim J, Kishnani P, Sun B
. An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond. Ann Transl Med. 2019; 7(13):289.
PMC: 6642933.
DOI: 10.21037/atm.2019.04.49.
View
11.
DeRuisseau L, Fuller D, Qiu K, DeRuisseau K, Donnelly Jr W, Mah C
. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A. 2009; 106(23):9419-24.
PMC: 2695054.
DOI: 10.1073/pnas.0902534106.
View
12.
Moore D, Keogh E, Eccleston C
. The interruptive effect of pain on attention. Q J Exp Psychol (Hove). 2011; 65(3):565-86.
DOI: 10.1080/17470218.2011.626865.
View
13.
McEwen B, Kalia M
. The role of corticosteroids and stress in chronic pain conditions. Metabolism. 2010; 59 Suppl 1:S9-15.
DOI: 10.1016/j.metabol.2010.07.012.
View
14.
Winkler M, von Landenberg C, Kuchenbecker K, Reimann J, Kornblum C
. Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease. Neuromuscul Disord. 2022; 32(3):195-205.
DOI: 10.1016/j.nmd.2022.01.001.
View
15.
Rabey M, Moloney N
. "I Don't Know Why I've Got this Pain!" Allostasis as a Possible Explanatory Model. Phys Ther. 2022; 102(5).
DOI: 10.1093/ptj/pzac017.
View
16.
Kohler L, Puertollano R, Raben N
. Pompe Disease: From Basic Science to Therapy. Neurotherapeutics. 2018; 15(4):928-942.
PMC: 6277280.
DOI: 10.1007/s13311-018-0655-y.
View
17.
Beckmann E, Jastrowski Mano K
. Advancing the Measurement of Executive Functioning in Pediatric Chronic Pain. Children (Basel). 2021; 8(8).
PMC: 8393994.
DOI: 10.3390/children8080630.
View
18.
Bhengu L, Davidson A, Du Toit P, Els C, Gerntholtz T, Govendrageloo K
. Diagnosis and management of Pompe disease. S Afr Med J. 2014; 104(4):273-4.
DOI: 10.7196/samj.7386.
View
19.
Schoser B, Laforet P, Kruijshaar M, Toscano A, van Doorn P, van der Ploeg A
. 208th ENMC International Workshop: Formation of a European Network to develop a European data sharing model and treatment guidelines for Pompe disease Naarden, The Netherlands, 26-28 September 2014. Neuromuscul Disord. 2015; 25(8):674-8.
DOI: 10.1016/j.nmd.2015.04.006.
View
20.
Nelson S, Bento S, Bosquet Enlow M
. Biomarkers of Allostatic Load as Correlates of Impairment in Youth with Chronic Pain: An Initial Investigation. Children (Basel). 2021; 8(8).
PMC: 8392178.
DOI: 10.3390/children8080709.
View